Search results
Thrombin (gamma-Form), Human
ZYMUTEST TAFI (Total) Antigen
High TAFI Ag concentrations involve a hypofibrinolytic status, which can induce an elevated risk of thrombosis. Measurement of TAFI Ag on plasma in order to diagnose a risk of a hypofibrinolysis resulting from an excess of TAFI.
TAFI Deficient Plasma
For any in vitro protocol or research study where a source of human TAFI deficient plasma is required.
CEPHEN APTT 5
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.
CEPHEN APTT 5
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.
CEPHEN APTT 2.5
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.
CEPHEN APTT 1
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.